Ted Okon, MBA: If you look at the CMS (Centers for Medicare & Medicaid Services) and the Center for Medicare & Medicaid Innovation Oncology Care Model (3 years in the making), it involved patient stakeholders and physician stakeholders. You had outside entities like Brookings and MITRE—and I don’t think the lower of cost or market (LCM) is perfect; I have some problems with it.
You can argue that it wasn’t thoughtful, it wasn’t deliberate, it wasn’t comprehensive, and it wasn’t open. We went in and talked to them (CMS) a lot. I sat on a lot of panels with a lot of CMS people—it was very open. Three years in the making.
Then, virtually out of nowhere (we only got a warning because a little notice to contractors was put up), it was taken down after an hour. But, it was air dropped in. You [could] look at it and say, “Where are the outside experts? Where are the patients? Where are the providers? Where are the payers in this? Who was consulting?”
It was nothing. This is what’s called the Medicare Part B Drug Payment Model. I use that term very loosely because that’s very different than the Oncology Care Model—which is a real model. So, we call the former model the Experiment on Cancer Care because that’s exactly what it is; it’s air dropped in. And CMS says, “Well, we’re going to reduce, basically, the multiplier on ASP (average sales price), and we’re going to give you a flat fee.” And by the way, disguised in that is the numbers that they produced. They are not really accurate because there’s a sequester cut on it. So, it’s not ASP + 2.5. It’s ASP + 0.86.
Then, there’s going to be a phase 2 to this that’s going to be about value and this mumbo jumbo. Of course, they don’t have any of that figured out—that’s just justification for calling this a model and, literally, reducing reimbursement.
Bruce A. Feinberg, DO: I’m going to end there. I want viewers to know we’re coming back in a few months, and I think those are exactly the 2 topics we’re likely going to be focusing on. They may be great topics for us to talk about at a future program.
This has been a great discussion today. We’ve reviewed and discussed a lot of information surrounding value-based care in oncology during this Summit. To close, I’d like to ask our panelists for their final thoughts.
James Gilroy: I think this is a representation of how decisions should be made within the healthcare environment—[meaning], with stakeholders like this at the table, first talking about things in concept and sharing ideas. Then, ultimately putting pen to paper.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More